69 results about "False positivity" patented technology

The invention discloses a HPV typing and integrated high-throughput sequencing detection method. The method selects the genes of the current HPV subtypes and combines the second-generation high-throughput sequencing technology to more comprehensively detect the type of HPV infection in patients. It overcomes the difficulties of low accuracy rate, high false positive rate, poor repeatability and high missed diagnosis rate of traditional detection methods. In the field of molecular diagnosis, the most direct and clear technology is gene sequencing. Compared with the current classic Sanger sequencing method, the second-generation high-throughput sequencing technology has higher detection throughput, faster sequencing speed, and higher accuracy. Advantages such as lower cost and richer information. With the help of the second-generation high-throughput sequencing technology, this method can accurately type high-risk HPV and low-risk HPV and detect whether it has been integrated with the human genome, and accurately and individually evaluate the tester to prevent The risk of lesions, thereby preventing the occurrence of tumors.

The present invention is to provide a simple membrane assay method for detecting or quantitating an analyte in a specimen sample using an assay device equipped with a membrane bound with a capture-substance to capture the analyte, comprising the steps of filtering a specimen sample using a filter, dropping the filtrate onto said membrane and detecting the presence of the analyte in said specimen sample, as well as a simple membrane assay kit for detecting the presence of an analyte in a specimen sample, comprising (1) a filter tube, and (2) an assay device equipped with a membrane bound with a capture-substance to capture the analyte. The method or the kit can decrease the occurrence of false positivity and can provide a highly accurate detection of the analyte such as pathogen and antibody in a specimen collected in a medical scene or by an individual.

Increased sensitivity and specificity of characterizing patient-specific variations as mutations that are indicative of a cancer or other disease by identifying patient-specific tumor mutations by comparing tumor and normal sequence reads from the patient and filtering for mutations that are unique to the tumor. By comparing tumor sequence to a normal sequence from the same patient, false-positivemutation calls are minimized in the analysis.

Disclosed is a thermostable DNA polymerase preparation which can illimitably reduce the risk of false positivity in the detection of a subject microorganism utilizing a gene amplification reaction and therefore enables the selective amplification of DNA for detecting the subject microorganism even when the amount of the subject microorganism is small and therefore the amount of DNA collected therefrom is extremely small, and can be produced at a reduced cost. Also disclosed is a method for quantifying or quantifying/identifying a subject organism to be detected rapidly, conveniently and with high sensitivity using the preparation of the present invention.

The invention discloses an ELISA kit for detecting a salmonella antibody. The kit comprises a solid-phase carrier coated with recombinant protein PagC, an enzyme-labeled antibody, salmonella negative serum and positive serum. The ELISA kit and method for detecting the salmonella antibody can be widely applied to salmonella, and application range is wide. The kit has high specificity and repeatability, the influence of temperature on reaction plates is small, and stability is high. Compared with an ELISA method with polysaccharide antigen as detection antigen, the method has the advantages that the occurrence rate of false positivity can be reduced to the maximum, and interference of other bacterial antigens in enterobacteriaceae on detection is avoided. Compared with a slide agglutination antigen detection method mostly adopted clinically, the method has the advantages that sensitivity and accuracy are higher, and detection throughput is increased greatly.

The invention relates to the field of data processing, discloses a prescription medication auditing method, device and equipment and a storage medium, and is applied to the field of smart medical treatment. According to the method, prescription information and diagnosis information are extracted from medical data of a patient; medicine feature information is extracted based on the prescription information; based on the medicine feature information and the diagnosis information, the matching degree of a medicine and the diagnosis information is calculated by utilizing an indication identification module; an expert rule base and a medical ontology knowledge base are integrated based on the matching degree; and the medication in the prescription information is audited so as to obtain the auditing result of the medication in the prescription. According to the invention, the detection rate and accuracy of mismatching of the medicine and indications are greatly improved, false negative and false positive prompts are reduced, the influence on normal diagnosis and treatment behaviors of doctors is reduced, complex clinical scenes of hospitals are met, the satisfaction degree of users is improved, medicine taking errors are reduced, and the medicine taking safety of patients is guaranteed. The invention also relates to a block chain technology, wherein the medicine feature information can be stored in the block chain.

The invention discloses an isothermal chain multiple displacement detection card of pathogen nucleic acid. The isothermal chain multiple displacement detection card of the pathogen nucleic acid utilizes the detection card which is prepared through a nucleic acid isothermal chain displacement method and a colloidal gold detection technology to carry out multiple detection on HBV-DNA, HCV-RNA, HIV-RNA, and TP-DNA. The isothermal chain multiple displacement detection card of the pathogen nucleic acid has the characteristics of simple and rapid operation, high sensitivity, and no need of professional equipment. The pathogen nucleic acid to be detected is not amplified in the detection process, so the detection card has the advantages of preventing amplified matter cross contamination in laboratories and preventing false positivity, can be widely used in high sensitivity pathogen nucleic acid detection in the fields of clinical detection, inspection and quarantine, infectious disease control, biological technology and the like, and has a wide application prospect.

The invention discloses a human enterovirus four-color fluorescence RT-PCR detection kit and a detection method; the detection kit comprises multiple fluorescence RT-PCR reaction mother liquor, AMV reverse transcriptase liquid, Taq DNA polymerase liquid, a positive control, and a negative control; the detection kit is characterized by further comprising an internal control, a multiple 10*PCR reaction buffer, bovine serum albumin with a concentration of 20 mg/ml, various forward primers and reverse primers with a concentration of 100 muM, and various specific probes with a concentration of 50 muM, wherein sequences of the forward primers, reverse primers, specific probes and the internal control are as shown in SEQIDNO. 1, NO. 2, NO.3, NO.4, NO.5, NO.6, NO.7. NO.8, NO.9, NO.10., NO.11., NO.12., and NO.13. The detection kit of the invention has the advantages of high detection sensitivity, good specificity, accuracy, high speed, and no false positivity.

The invention provides a graphene accelerated PCR (polymerase chain reaction) technology, in particular an integrated novel modified PCR technology integrating a novel material graphene and PCR and being capable of accelerating nucleic acid amplification, and aims to increase contact between nucleic acid molecules, accelerate PCR process and reduce nonspecific amplification in a PCR system by utilizing the characteristics of adsorption and high-specific surface of graphene. The graphene accelerated PCR technology relates to the field of nucleic acid amplification in molecular biology and molecular tests, is a theoretical innovation integrating the novel material graphene and PCR detection, and can be used for increasing the contact probability of nucleic acid molecules by utilizing the characteristics of adsorption and high-specific surface of graphene, integrating a PCR to slowly release one or various ingredients, combining mineral oil or liquid petrolatum to seal and isolate the external environment, and solving the problem of false positivity caused by over-long reaction time of the PCR and increase of nonspecific amplification due to over-long reaction time of the PCR.

The invention relates to an intelligent diagnosis system for new coronal pneumonia based on deep learning, and belongs to the field of medical image processing. The system comprises a control unit, an intelligent detection and diagnosis unit, a storage unit and a three-dimensional display unit, the control unit is used for inputting and modifying system data; the intelligent detection and diagnosis unit is used for predicting new coronal pneumonia cases; the intelligent detection and diagnosis unit comprises a data preprocessing module, a focus area detection module, a false positive removal module and a case prediction module. The deep learning network diagnosis system combining three parts of detection, false positive removal and prediction is adopted to output the diagnosis result, the problems that the focus is too small and is not easy to detect, the information of a single local focus is too little, the misdiagnosis rate is too high and the like are solved, the problem that the number of medical samples is too small is solved, the diagnosis efficiency is greatly improved, and the diagnosis accuracy is improved. Therefore, treatment efficiency of a patient can be improved, and clinical data can be accumulated.

The invention relates to the G test detection technical field, and particularly discloses a method for eliminating false positive interference of a G test, that is to say, a buffer solution containing a divalent soluble metal salt and Tris is prepared and is mixed with patient plasma or serum containing an interfering substance to prepare a detection sample, and the detection sample is subjected to the G test. With the use of the method, when the patient plasma/serum containing a nonspecific tachypleus amebocyte lysate is detected, the interference effect can be eliminated, the beta-G concentration in the patient plasma/serum is accurately detected, and patient mental and economic burdens caused by clinical misjudgment are greatly reduced.

The invention discloses a ROS1 fusion gene ARMS fluorescent quantitative typing detection kit. The kit comprises a positive primer for detecting a ROS1 fusion body variant, a common reverse primer and a fluorescence probe, wherein the positive primer is at least one of ten single-chain DNAs as shown in SEQ ID NO.1 to SEQ. ID NO. 10; the common reverse primer is at least one of three single-chain DNAs as shown in SEQ ID NO.11 to SEQ ID NO.13; and the fluorescence probe is at least one of three single-chain DNAs as shown in SEQ ID NO.14 to SEQ ID NO.16. The invention further discloses a method for detecting the ROS1 fusion gene variant. The specific primers and fluorescence probe are designed for the ROS1 fusion gene variant, so that the sensitivity and specificity for ROS1 fusion gene variant detection are improved, and the false positivity is low.

The invention belongs to the technical field of bacterial detection, and specifically discloses a multi-fluorescent PCR kit and method for detecting clostridium difficile genes and toxin genes, wherein the kit and method not only can identify clostridium difficile but also can detect toxin B genes. The kit mainly comprises a specific primer group and a probe, the primer group and the probe are composed of a primer pair and probe for detecting clostridium difficile, a primer pair and probe for detecting toxin B, and an internal primer pair and probe. By design of the specific primers and probes, the clostridium difficile genes and the toxin genes can be detected from samples with complex components. The kit has the advantages of simple operation, short reporting time, high specificity, highsensitivity and good accuracy; PCR false negativity is avoided by introducing internal standard products, false positivity caused by contamination of amplified products is reduced, and the kit is suitable for pathogenesis screening of patients with diarrhea of unknown clinical cause.

The invention relates to a urinary cytology artificial intelligence urinary tract epithelium cancer identification system. The system includes: a data classification module used for classifying urinary cytology data acquired in advance to obtain a urinary cytology positive data set and a urinary cytology negative data set, and matching the urinary cytology positive data set and the urinary cytology negative data set based on an operation pathology result to obtain a true positive data set, a false positive data set, a true negative data set and a false negative data set; a data grouping module which is used for grouping various data sets obtained by the data classification module to obtain a training-verification set and a test set; a model training module which is used for training a pre-constructed model to obtain a final model; a model testing and auditing module which is used for performing cell level testing and tissue level testing on the obtained final model; and an identification module which is used for identifying the to-be-identified urinary cytology data to obtain an identification result. The system can be widely applied to the field of cytology pathology recognition.

The invention belongs to the technical field of virus detection, and specifically relates to a real-time fluorescent quantitative PCR detection primer probe set, kit and method of porcine circovirus type 3. The detection accuracy is enhanced by designing primers on PCV3 cap protein in the invention for the first time; a fully closed tube operation is achieved in the detection method, the occurrence of false positive phenomenon is reduced, and at the same time, the high specificity of TaqMan probe technology and the high sensitivity of spectroscopy technology not only overcome the shortcoming of conventional PCR technology that can only achieve qualitative detection, but also solve the shortcoming of an SYBR Green method with poor specificity, and the detection method is more suitable for clinical testing; and the method has high sensitivity, good specificity and good reproducibility, the lowest detection limit is 11.8 copies/[mu]L, and the detection method is more sensitive than otherfluorescent quantitative PCR detection methods.

The invention belongs to the field of crop pathogenic bacterial generative propagation type identification and particularly relates to a method for rapidly detecting rice aspergillus mating type genes through multiple PCR. The method is specially used for detecting rice aspergillus generative propagation mating type genes and comprises the steps of rice aspergillus isolated culture, rice aspergillus genomic DNA preparation and storage for use, PCR, gel electrophoresis detection and the like. The method has the advantages that operation is easy and rapid, and sensitivity is high; the accuracy of rice aspergillus generative propagation mating type gene detection and mating type identification is effectively improved, amplification specificity is guaranteed, amplification efficiency is improved, and false positivity and nonspecific positivity cannot be caused.

The invention relates to a Toxoplasma gondii tandem multi-epitope gene ELISA detection kit. The kit is characterized in that serum to be detected is diluted with a sample, 100 [mu]l of the diluted serum to be detected is added to a 96-well ELISA plate<(1)> and is incubated for at 37 DEG C for 1 h, and positive control, negative control and blank control are arranged; the incubated serum to be detected is washed with a washing liquid for 3 min every time and is washed 5 times; a rabbit anti-sheep IgG-HRP conjugate is added, and acts at 37 DEG C for 1 h, the obtained material is washed with the washing liquid for 3 min every time and is washed 5 times; and a chromogenic substrate solution is added, a substrate A and a substrate B are mixed according to a ratio of 1:1, 100 [mu]l of the obtained substrate mixture is added to the ELISA wells, shady coloration is carried out for 15 min, 50 [mu]l of a stopping solution is added, and the OD490 value is detected; and the inhibition rate PI = (OD negative control - OD sample)/OD negative control * 100%, the sample is positive if the PI is not less than 50%, and the sample is negative if the PI is less than 50%. The kit has the advantages of mature method, high repeatability, and effective reduction of false positivity and non-repeatability in the detection of the Toxoplasma gondii, and can be operated by general researchers.

The invention belongs to the technical field of biology, and particularly relates to the technical field of rapid detection of lung cancer related genes. An obtained fluorescence probe for rapid detection of lung cancer ALK gene rearrangement does not contain repeated sequences, can avoid cross reactions and has the advantages of being high in accuracy, good in specificity and low in false positivity, a rapid fluorescence in situ hybridization is utilized for shortening the hybridization time which is originally 16 h to be 2 h, the diagnosis efficiency is greatly improved, and time is saved.

The invention discloses a method for establishing a metagenomics pathogen detection reference threshold. The method comprises the following steps: determining a clinical sample type; determining components and a human cell content distribution range; setting gradient negative control; carrying out multi-batch repeated testing on negative control samples according to a metagenome detection process to be carried out on the clinical sample to be tested; counting detection sequence numbers of different pathogens in the negative control samples with different human cell concentrations to obtain a detection sequence number fluctuation interval of the corresponding pathogens in the negative control samples with different human cell concentrations; and taking 120% of the upper limit of the fluctuation interval of the detection sequence number of the corresponding pathogen in the negative control sample as a threshold value. According to the method, layered discrimination of sample detection results can be realized, and the accuracy of metagenomics pathogen detection results is improved; the report interpretation efficiency can be improved; the false positive of a metagenome detection result can be effectively reduced; pollution in the detection process can be evaluated in real time, and laboratory process improvement is guided.